A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test
NCT ID: NCT05634473
Last Updated: 2022-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
280 participants
INTERVENTIONAL
2022-12-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population
NCT05870436
A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma
NCT02100267
Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma
NCT02097537
A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population
NCT02104284
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with asthma/healthy subjects
Methacholine Chloride
Cholinergic agonists
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methacholine Chloride
Cholinergic agonists
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2 Normal or abnormal pulmonary function test without clinical significance (FEV1 ≥ 70% predicted);
* 3 Voluntary, signed informed consent, good compliance, can cooperate with the trial observation.
Patients with asthma:
* 4 Clinical diagnosis of asthma patients;
* 5 Patients who can stop using prohibited concomitant drugs (β2 adrenoceptor agonists, anticholinergics, oral bronchodilators, antihistamines, leukotriene receptor antagonists) within the specified period before airway allergic examination;
Healthy subjects:
* 6 Body mass index (BMI) = weight (kg)/height2 (m2), and body mass index is within the range of 18.5 \~ 27.0 (including the critical value).
Exclusion Criteria
* 1 Patients with a past history of allergy to this type of reagent;
* 2 Patients with a history of heart disease who are difficult to adapt to bronchial provocation test;
* 3 Patients who have undergone thoracic or abdominal surgery within 6 months before the trial;
* 4 Patients who have undergone surgery for intracranial, ophthalmic diseases, ear, nose and throat diseases, and respiratory diseases 6 months before the trial;
* 5 Complicated pneumothorax and other respiratory diseases or tuberculosis and other infectious diseases;
* 6 Patients with diseases that may be affected by the use of cholinergic drugs (epilepsy, bradycardia, coronary artery occlusion, vagal tension, thyroid disease, arrhythmia, peptic ulcer, urinary tract disorders, etc.);
* 7 Patients with a past history of drug dependence or alcohol dependence;
* 8 Previous severe circulatory system diseases, hepatobiliary system diseases, digestive tract diseases, urinary system diseases, kidney diseases, blood diseases, endocrine system diseases, immune system diseases, malignant tumors, etc.;
* 9 Patients who are using cholinase inhibitors (treatment of myasthenia gravis);
* 10 Patients with unexplained urticaria;
* 11 Pregnant and lactating women;
* 12 Subjects with dyspnea, wheezing, wheezing on the day of the trial;
* 13 Patients with myocardial infarction or stroke, combined with hypertension (systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg);
* 14 Poor cooperation in basic pulmonary function tests, not in line with quality control;
* 15 Use of drugs that will affect airway systolic function and airway inflammation, thereby affecting airway reactivity and can not be discontinued before the test (bronchodilator drugs, glucocorticoids, anti-allergic drugs and triene receptor antagonists and others);
* 16 Current smokers, those who quit for less than one year at the time of screening, and those with a smoking history of more than 10 packs/year;
* 17 Abnormalities in physical examination, laboratory tests, vital signs and test-related tests are clinically significant (based on clinician judgment);
* 18 The investigators think that there are any unsuitable for inclusion;
Patients with asthma:
* 1 Hospitalized for asthma exacerbation within 12 weeks;
* 2 Patients with combined respiratory diseases (such as COPD, etc.) that may affect the efficacy and safety evaluation of the drug;
Healthy subjects:
* 1 Have used any drugs in 2 weeks;
* 2 Patients, immediate family members suffering from allergic diseases (allergic rhinitis, specific rhinitis, allergic conjunctivitis, chronic urticaria, food allergy, etc.);
* 3 Patients with upper respiratory tract infection, acute sinusitis and other infection-related symptoms or have received treatment in 6 weeks.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Guangdong Province Hospital of chinese medicine
Guangzhou, Guangdong, China
Liuzhou people's Hospital
Liuzhou, Guangxi, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
The Affiliated Hospital of Inner Mongolia Medical Univercity
Hohhot, Inner Mongolia, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Benxi Central Hospital
Benxi, Liaoning, China
Weifang NO.2 People's Hospital
Weifang, Shandong, China
West China Hospital，Sichuan University
Chengdu, Sichuan, China
Zhejiang Provincial Hospital of Chinese Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQC3610-CS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.